Home » Stocks » IVA

Inventiva SA (IVA)

Stock Price: $15.87 USD -0.20 (-1.24%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 614.58M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $15.87
Previous Close $16.07
Change ($) -0.20
Change (%) -1.24%
Day's Open 16.00
Day's Range 15.44 - 17.40
Day's Volume 21,600
52-Week Range 9.87 - 17.40

News

There are no news available yet.

About IVA

Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE fo... [Read more...]

Industry
Biotechnology
IPO Date
Jul 10, 2020
CEO
Frederic Cren
Employees
86
Stock Exchange
NASDAQ
Ticker Symbol
IVA
Full Company Profile

Financial Performance

In 2019, Inventiva's revenue was $11.29 million, an increase of 53.02% compared to the previous year's $7.38 million. Losses were -$30.22 million, -8.47% less than in 2018.

Financial Statements